Latest Earnings
Equities
Stock Analysis
Stock Movers
Deals
Gainers And Losers
IPOs
Technology
Artificial Intelligence
Web Stories
Benzinga Inspire
Piramal Pharma
This Midcap Stock Has Slumped Over 20% In 6 Months, But Analyst Sees Turnaround Potential With 40% Upside
Shares of Piramal Pharma have had a rough time at the bourses. The Piramal Group company that demerged from Piramal Enterprises last year has slumped over 20% since the start of the year. But analysts at Nuvama expect a strong recovery in the overall business in subsequent years.
This Midcap Stock Has Slumped Over 20% In 6 Months, But Analyst Sees Turnaround Potential With 40% Upside
